CytomX Therapeutics Third Quarter 2026 Financial Results - CYTOMX THERAPEUTICS INC

Financial Performance:

• Total revenue for Q3 2026 was $1.7 million, a decrease from $6.0 million in Q3 2025, primarily due to the conclusion of the Astellas collaboration in Q2 2026.
• Cash and investments totaled $348 million as of September 30, 2026, up from $330 million at the end of June 2026, including a $37 million payment from Regeneron for expanded collaboration targets.
• Operating expenses were $25.2 million in Q3 2026 compared to $21.7 million in Q3 2025.
• Research and development (R&D) expenses reached $16.5 million, an increase of $1.2 million year-over-year, driven by higher personnel costs, partially offset by lower Varsetta-M manufacturing timing expenses.
• General and administrative (G&A) expenses rose to $8.7 million from $6.4 million, attributed to increased personnel and consulting costs.
• The company projects a cash runway extending into the second half of 2028.

Guidance and Future Outlook:

• Varsetta-M is on track to enter its first potential registrational study in the first half of 2027.
• An integrated Phase 1 update, including the first look at overall survival (OS) and potential registrational strategy, is anticipated in January 2027.
• Initial clinical data from the Varsetta-M and Bevacizumab combination study is expected in the first half of 2027.
• A new Phase I-II trial evaluating Varsetta-M in combination with Bevacizumab, 5-fluorouracil, and leucovorin for second-line CRC is scheduled to initiate by year-end 2026.
• Phase 1 enrollment for Varsetta-M in pancreatic ductal adenocarcinoma and biliary tract cancer has already commenced.
• The company aims to advance Varsetta-M from monotherapy to earlier-line combinations to potentially replace standard of care.

Business Segments and Product Lines:

• Varsetta-M: An EPCAM-targeting topo-1 antibody-drug conjugate (ADC) using ProBody platform technology; currently the lead asset with over 100 patients enrolled in Phase 1.
  • Progression-free survival at 8.6 and 10 mg/kg doses has exceeded current standard of care in heavily pretreated metastatic colorectal cancer (CRC) patients.
  • Dose optimization is underway comparing 8.6 and 10 mg/kg every three weeks using adjusted ideal body weight (AIBW) dosing and prophylaxis to manage GI toxicity.
  • Targeting 35,000 addressable patients in the US for third-line or later metastatic CRC.
• CX801: A masked interferon alpha 2B program for checkpoint refractory melanoma.
  • Phase 1 monotherapy enrollment has exceeded the approved dose levels of unmasked interferon.
  • Biomarker data supports the mechanism of action for combination therapy with Keytruda.
  • Initial data from the Phase 1 combination study is expected in the first half of 2027.
• Pipeline Expansion: Varsetta-M is being evaluated in gastric, gastroesophageal junction, and EPCAM-selected pancreatic and biliary tract cancers.

Market and Competitive Landscape:

• Varsetta-M is positioned as the first-in-class EPCAM-directed ADC in clinical development.
• The competitive ADC landscape in CRC is evolving, with programs from AstraZeneca, Takeda, Merck-Serono, and PreSens-CTC, including emerging CDH17 ADCs.
• Management views the field's evolution as validating the ADC approach for CRC and emphasizes Varsetta-M's differentiation via its proprietary masking technology.
• The metastatic CRC market is characterized by high unmet need, with Varsetta-M aiming to capture a significant portion of the fragmented third-line plus market.

Risks and Challenges:

• Toxicity Management: High-grade diarrhea remains a key safety challenge; the company aims to manage Grade 3 diarrhea rates to 20% or below using prophylaxis and dose optimization.
• Combination Toxicity: Potential for increased gastrointestinal toxicity when combining Varsetta-M with 5-fluorouracil requires careful evaluation.
• Clinical Endpoints: The definition of the appropriate patient population and comparator for the pivotal Phase 1/2 registrational study remains under evaluation.
• Market Adoption: Success depends on demonstrating superiority over fragmented standard of care options in the third-line plus setting.

Management Commentary and Tone:

• Tone was highly confident and urgent, emphasizing the "significant unmet need" in CRC and the "strong potential" of Varsetta-M.
• Dr. McCarthy described the year as "highly productive," highlighting the strategic shift from monotherapy in CRC to broader pan-tumor potential.
• Management reiterated discipline in capital allocation to prioritize Varsetta-M's progression toward registration.
• CEO expressed encouragement regarding the safety profile, noting the "remarkably low rate of hematologic toxicity" compared to other Topo-1 ADCs.

Analyst Questions and Answers:

• BEV Chemo Combo Study: Confirmed the study will initially enroll late-stage patients for Phase 1 dose-finding before expanding to second-line patients in Phase 2; enrollment numbers were not disclosed.
• OS Thresholds: Management is benchmarking against the ~9 months OS of the Bev/Long-Surf regimen but has not yet decided on a specific third-line vs. fourth-line indication, prioritizing optimal study design and comparator selection.
• Safety Endpoints: Primary focus for safety is on GI toxicity; the switch from Irinotecan to Varsetta-M is expected to mitigate hematologic toxicity, though GI management remains critical.
• Data Timing: The January update timing was driven by the need for sufficient patient follow-up on safety/efficacy and regulatory engagement, not solely FDA feedback or conference logistics.
• Dose Selection: No specific Phase 3 dose has been finalized; dose selection and granularity on AIBW impact will be addressed in the January update.
• Target Profile: EPCAM is viewed as highly broadly expressed; management did not provide specific data on shedding rates compared to CEA/CCAM5, stating it is not a primary differentiator currently.

Other Key Points:

• Varsetta-M's unique ProBody masking technology is a core differentiator intended to minimize systemic exposure and reduce toxicity.
• The company has shifted focus from exclusively developing in CRC to a pan-tumor strategy targeting EPCAM-expressing solid tumors.
• The $37 million Regeneron payment was a specific driver of the cash balance increase, highlighting the value of the expanded collaboration.
• Management reiterated that Overall Survival (OS) will likely be the primary endpoint for the initial randomized registrational study.